Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies

PURPOSE OF REVIEW: [(177)Lu]Lu-PSMA-617 is a radiopharmaceutical that emits beta-minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate cancer. Despite its clinical success, there are still patients not showing sufficient response rates. This review compiles latest s...

Descripción completa

Detalles Bibliográficos
Autores principales: Arbuznikova, Daria, Eder, Matthias, Grosu, Anca-Ligia, Meyer, Philipp T., Gratzke, Christian, Zamboglou, Constantinos, Eder, Ann-Christin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640479/
https://www.ncbi.nlm.nih.gov/pubmed/37861915
http://dx.doi.org/10.1007/s11912-023-01458-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640479/
https://www.ncbi.nlm.nih.gov/pubmed/37861915
http://dx.doi.org/10.1007/s11912-023-01458-6

Ejemplares similares